Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2017

01-08-2017

Performance of 4T score and heparin–platelet factor 4 antibody in the diagnosis of heparin-induced thrombocytopenia (HIT) in cancer

Authors: Myra Wong, Thein Hlaing Oo, Wei Qiao, Naveen Garg, Cristhiam M. Rojas-Hernandez

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2017

Login to get access

Abstract

Cancer patients have characteristics which significantly influence the 4T score and heparin–platelet factor 4 antibody (H-PF4 ab). Our aim was to determine among cancer patients the correlation of the 4T score and H-PF4 ab with the serotonin release assay (SRA). We performed a retrospective analysis of records of cancer patients in whom H-PF4 polyclonal (IgG, IgM and IgA) enzyme-linked immunosorbent assay (ELISA) and SRA were evaluated. Cases were defined as heparin induced thrombocytopenia (HIT) when SRA confirmed the diagnosis. Logistic regression model and the receiver operating characteristic curves were conducted to identify the optimal cutting point for the optical density (OD) and 4T score to discriminate the SRA status. Among 246 patients, the optimal cutoff of 4T score for HIT diagnosis was 5 (sensitivity 90.0%, specificity 73.6%), and the optimal cutoff of H-PF4 polyclonal ELISA OD was 1.004 (sensitivity 81.8%, specificity 97.0%). Our findings suggest that cancer patients may need higher cutoff values for the 4T score. Conventional H-PF4 ab testing seem to perform similarly for the diagnosis of HIT when compared to published data from non-cancer cohorts. Additional studies are necessary to confirm our findings.
Literature
2.
go back to reference Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332(20):1330–1335. doi:10.1056/NEJM199505183322003 CrossRefPubMed Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332(20):1330–1335. doi:10.​1056/​NEJM199505183322​003 CrossRefPubMed
4.
go back to reference Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A (2003) The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101(8):2955–2959. doi:10.1182/blood-2002-07-2201 CrossRefPubMed Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A (2003) The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101(8):2955–2959. doi:10.​1182/​blood-2002-07-2201 CrossRefPubMed
5.
go back to reference Prandoni P, Siragusa S, Girolami B, Fabris F, BELZONI Investigators Group (2005) The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 106(9):3049–3054. doi:10.1182/blood-2005-03-0912 CrossRefPubMed Prandoni P, Siragusa S, Girolami B, Fabris F, BELZONI Investigators Group (2005) The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 106(9):3049–3054. doi:10.​1182/​blood-2005-03-0912 CrossRefPubMed
8.
go back to reference Oliveira GB, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, Moliterno DJ, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Ohman EM, Granger CB, Complications After Thrombocytopenia Caused by Heparin Registry Investigators (2008) Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 168(1):94–102. doi:10.1001/archinternmed.2007.65 CrossRefPubMed Oliveira GB, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, Moliterno DJ, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Ohman EM, Granger CB, Complications After Thrombocytopenia Caused by Heparin Registry Investigators (2008) Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 168(1):94–102. doi:10.​1001/​archinternmed.​2007.​65 CrossRefPubMed
10.
go back to reference Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M, American College of Chest Physicians (2012) Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2Suppl):e495S–e530S. doi:10.1378/chest.11-2303 CrossRefPubMedPubMedCentral Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M, American College of Chest Physicians (2012) Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2Suppl):e495S–e530S. doi:10.​1378/​chest.​11-2303 CrossRefPubMedPubMedCentral
Metadata
Title
Performance of 4T score and heparin–platelet factor 4 antibody in the diagnosis of heparin-induced thrombocytopenia (HIT) in cancer
Authors
Myra Wong
Thein Hlaing Oo
Wei Qiao
Naveen Garg
Cristhiam M. Rojas-Hernandez
Publication date
01-08-2017
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2017
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-017-1523-z

Other articles of this Issue 2/2017

Journal of Thrombosis and Thrombolysis 2/2017 Go to the issue